Biomarker Discovery
Biomarker Discovery
Through its unique collaboration with the UMC Utrecht and its Athero-Express study, CAVΛDIS™ has access to a state-of-the-art biomarker discovery platform, enabling the company to identify and validate novel biomarkers predictive for cardiovascular diseases.
Bookmark and Share

Discovery Platform

The Athero-Express Biobank Study (, worldwide one of the largest biobank studies with a longitudinal study design, offers us a unique opportunity to link protein expression in plasma and vessel wall tissue to long-term clinical outcome. This ongoing study was initiated in 2002 and over 2,500 plasma and plaque samples have been collected to date, while more than a 1,000 patients have reached a clinical endpoint during the 3 years follow-up.

Recently CAVΛDIS™ focused its biomarker discovery research on exosomes, which are secreted cellular particles that contain many biologically active proteins, RNA and miRNAs. The biomarker properties of these micro-particles are relatively unexplored in cardiovascular disease, but first results show that this approach holds a strong promise. This shift in research focus yielded a series of novel biomarkers with strong predictive value for coronary artery disease (CAD).

  • The Athero-Express Biobank Study is a unique and state-of-the-art biomarker discovery platform.
  • CAVΛDIS™ identified several novel exosome-based biomarkers with a strong predictive value for coronary artery disease (CAD).
  • CAVΛDIS™ biomarkers show an impressive shifting power (Net Reclassification Index) in patients that are classified as having a high or low risk based on traditional risk factors.
  • CAVΛDIS™ biomarkers are being developed for individual risk assessment, for use as surrogate endpoint in clinical trials and for therapeutic target identification.
Related items
Our mission
CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. The company's mission is to identify patients at risk of developing heart attacks and strokes. Our ultimate goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
read more